Wednesday, March 14, 2012 7:23:48 PM
Some Merger and Acquisition Formalities. This article was written by a Merger and Acquisition manager regarding how to sell your business. Take heed to this note in particular:
"In return for that, the buyer will usually require a quiet period. That means that for the due diligence period – usually 30 to 60 days, the M&A advisors are precluded from shopping the deal any further to other potential buyers. This is also called a standstill. If the due diligence is completed without major incident, the buyer's team starts preparing the definitive purchase agreement."
"
Think about Oracle trying to sell a $500,000 software project to Fortune 500 companies with a mailing. What about IBM selling a large company on a 10-year $150 million data center outsourcing project with an email blast?"
http://www.articlesbase.com/advertising-articles/selling-a-business-new-rules-for-merger-and-acquisition-success-1783769.html
Wow, this sounds very familiar!
"In return for that, the buyer will usually require a quiet period. That means that for the due diligence period – usually 30 to 60 days, the M&A advisors are precluded from shopping the deal any further to other potential buyers. This is also called a standstill. If the due diligence is completed without major incident, the buyer's team starts preparing the definitive purchase agreement."
"
Think about Oracle trying to sell a $500,000 software project to Fortune 500 companies with a mailing. What about IBM selling a large company on a 10-year $150 million data center outsourcing project with an email blast?"
http://www.articlesbase.com/advertising-articles/selling-a-business-new-rules-for-merger-and-acquisition-success-1783769.html
Wow, this sounds very familiar!
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
- Nasdaq Top 5 Premarket Losers • IH Market News • 05/20/2025 12:47:37 PM
- Protagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma Firm • IH Market News • 05/19/2025 02:28:09 PM
- Nasdaq Top 5 Premarket Gainers • IH Market News • 05/19/2025 01:07:08 PM
